Clinical Trial Update: Study of Itacitinib for the Prophylaxis of Graft-Versus-Host Disease and Cytokine Release Syndrome After T-cell Replete Haploidentical Peripheral Blood Hematopoietic Cell Transplantation [Phase 1]

View source ↗

Summary

Phase 1 study evaluating itacitinib for prophylaxis of graft-versus-host disease and cytokine release syndrome after T-cell replete haploidentical peripheral bl…

Upgrade for the full analysis, importance score, and drug timeline.

Diseases / indications

• Acute Lymphoblastic Leukemia
• Acute Myeloid Leukemia
• Hodgkin Lymphoma
• Myelodysplastic Syndromes
• Non-hodgkin Lymphoma

Drugs mentioned

• Itacitinib (itacitinib)

Snippet

Sponsor: Washington University School of Medicine | Conditions: Acute Myelogenous Leukemia, Acute Lymphocytic Leukemia | Phase 1 | Status: COMPLETED | Results posted: 2025-04-06